Latest Headlines

Latest Headlines

China Biologic subsidiary inks deal to source raw plasma

China Biologic Products said its subsidiary, Guizhou Taibang Biological Products, has signed a deal with Xinjiang Deyuan Bioengineering to source 500 tons of raw plasma over the next three years, the company said in a news release.

Japan's SymBio partners with Medicines Co. on pain reliever Ionsys

Japan's SymBio will develop and commercialize pain medicine Ionsys in an exclusive licensing deal with the U.S.-based Medicines Co., marking its first product in the Japanese market and a company push to expand abroad.

Servier hands some cancer candidates to Horizon with £50M on the line

French drugmaker Servier has outlicensed some early-stage cancer treatments to Horizon Discovery, holding on to the rights to buy them back if they come through in preclinical development.

OptiNose raises up to $30M to get drug-device combo through FDA

Specialty pharma OptiNose hopes to use up to $30 million in new financing to get its OPN-375 in combination with its novel breath-powered device through the FDA. But the agency already demonstrated some skepticism around the device last year--it issued a complete response letter to OptiNose partner Avanir because of device errors and required further testing.

Shanghai-based biotech Ark Biosciences successfully completes PhI on RSV candidate

Venture-backed Ark Biosciences has successfully completed a Phase I clinical trial of work on anti-respiratory syncytial virus (RSV) candidate AK0529, hitting a key milestone for the respiratory viral infection and viral hepatitis focused company.

GSK obtains rights to inhaled nanoparticles made using Liquidia's PRINT platform

GlaxoSmithKline now has rights to develop inhaled therapeutics using Liquidia's PRINT particle engineering technology. The development builds on a drug delivery alliance between the two companies that commenced in 2012.

Perrigo licenses Flamel's oral suspension delivery platform to develop additional OTC meds

As part of its so-called Base Plus Plus Plus strategy, specialty pharmaceutical company Perrigo announced that it is licensing Flamel's LiquiTime extended-release suspension to develop products for the U.S. over-the-counter market.

Regeneron inks a $325M deal, selling Asian rights to a pain treatment

Regeneron is handing off the Asian rights to its in-development musculoskeletal pain treatment for up to $325 million, handing the antibody over to a subsidiary of Japanese giant Mitsubishi.

Illumina expands in China with cancer Dx deal

Illumina is joining forces with China's Amoy Diagnostics to create next-generation sequencing cancer tests for the Chinese clinical market, expanding its footprint in the country while strengthening its commitment to developing innovative technology for the disease.

Facing a crisis, Xoma buys time with a $517M Novartis deal

Xoma has worked a deal to outlicense a cancer antibody to its longtime partners at Novartis. In the deal Xoma will get $37 million in badly needed cash upfront, some relief on $13.5 million in debt and the chance to earn $480 million in milestones, if all goes as planned.